The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”

作者：Marco Donatello Delcuratolo, Veronica Crespi, Giorgio Saba, Andrea Mogavero, Valerio Maria Napoli, Edoardo Garbo, Massimiliano Cani, Antonio Ungaro, Maria Lucia Reale, Alessandra Merlini, Enrica Capelletto, Paolo Bironzo, Mario Levis, Umberto Ricardi, Silvia Novello, Francesco Passiglia · 发表于：Cancer Treatment Reviews · 年份：2025 · DOI：10.1016/j.ctrv.2025.102918 · 被引用次数：7 · 研究领域：Lung Cancer Diagnosis and Treatment、Lung Cancer Treatments and Mutations、Lung Cancer Research Studies

Despite PACIFIC set a new milestone in the clinical management of unresectable stage III non-small cell lung cancer (NSCLC), it left some critical questions pending for clinical research: the efficacy of durvalumab in the real-world setting; the activity of less intensive regimens for frail populations; the role of targeted therapies in oncogene-addicted tumors; the selection of subsequent strategies at immunotherapy failure; the efficacy of novel and intensified treatments; the role of molecular biomarkers for patients' selection. This review aims to describe the evolving landscape of unresectable stage III NSCLC and provides an updated overview of the available evidence, analyzing lights and shadows emerging from recent clinical trials and discussing the most relevant challenges of post-PACIFIC era.